Company profile
Vicapsys Life Sciences, Inc.
OTC: VICP · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 50
v0.1 · 5/100 weight · pillars only
↑ listing tenure, market scale · ↓ Altman-Z, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.2M
Employees
2
as of 2026-08-19
Market cap
$46.9M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$1.2M-$1.2M2023
Operating income-$1.0M-$1.0M2023
Total assets$39.7k$39.7k2023
Equity-$1.9M-$1.9M2023
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Vicapsys Life Sciences, Inc.’s financial profile?
Vicapsys Life Sciences, Inc. earned -$1.2M in FY2023 net income.
Peers · Healthcare
BioStem Technologies, Inc.——Apollomics, Inc.——Mach7 Technologies Limited——Context Therapeutics Inc.——Cell Source, Inc.——Rocket Doctor AI Inc.——Key facts
CEOFederico Pier
SectorHealthcare
IndustryBiotechnology
HeadquartersCumming, GA
ExchangeOTC: VICP
Employees2
IPO date1998-02-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.